Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors.

about

Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors.

Item

http://www.wikidata.org/entity/Q52579088

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Discovery of Novel Indoleamine ...... tylase (HDAC) Dual Inhibitors.

@en

Discovery of Novel Indoleamine ...... tylase (HDAC) Dual Inhibitors.

@nl

type

Item

label

Discovery of Novel Indoleamine ...... tylase (HDAC) Dual Inhibitors.

@en

Discovery of Novel Indoleamine ...... tylase (HDAC) Dual Inhibitors.

@nl

prefLabel

Discovery of Novel Indoleamine ...... tylase (HDAC) Dual Inhibitors.

@en

Discovery of Novel Indoleamine ...... tylase (HDAC) Dual Inhibitors.

@nl

P1476

Discovery of Novel Indoleamine ...... etylase (HDAC) Dual Inhibitors

@en

P2093

Chunquan Sheng

http://www.w3.org/2001/XMLSchema#string

Guoqiang Dong

http://www.w3.org/2001/XMLSchema#string

Kun Fang

http://www.w3.org/2001/XMLSchema#string

Shanchao Wu

http://www.w3.org/2001/XMLSchema#string

Shipeng He

http://www.w3.org/2001/XMLSchema#string

Ying Wu

http://www.w3.org/2001/XMLSchema#string

Yu Li

http://www.w3.org/2001/XMLSchema#string

P2860

Histone deacetylase inhibitors: Potential in cancer therapy

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

The future of immune checkpoint therapy

The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma.

Histone deacetylases and transcriptional therapy with their inhibitors.

Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.

Big opportunities for small molecules in immuno-oncology.

Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase (IDO), a novel target in cancer disease.

P304

312-317

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/ACSMEDCHEMLETT.7B00487

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Wei Wang

P577

2018-03-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29670692

http://www.w3.org/2001/XMLSchema#string

P932

5900342

http://www.w3.org/2001/XMLSchema#string